Skip to main content
. 2014 Apr 28;18(2):R83. doi: 10.1186/cc13845

Table 2.

Suspected VAP episode description according to statin exposure and outcome

  Overall
 Statin previous users
 Statin-naive patients
 P
(n = 349) (n = 93) (n = 256)
Time elapsed between ICU admission and VAP (days)
 10.0 (2.0-157.0)
 10.0 (2.0-72.0)
 10.0 (2.0-157.0)
 0.62
Time elapsed between MV onset and VAP (days)
 10.0 (2.0-156.0)
 10.0 (2.0-69.0)
 10.0 (2.0-156.0)
 0.48
Early VAP (n (%))
 108 (30.9)
 27 (29.0)
 81 (31.6)
 0.64
Septic shock (n (%))
 117 (33.6)
 35 (38.0)
 82 (32.0)
 0.29
Appropriate antibiotic therapy (n (%))
 262 (76.4)
 70 (76.9)
 192 (76.2)
 0.89
Concurrent therapy during VAP period
  
 Steroids (n (%))
 153 (45.0)
 41 (45.1)
 112 (45.0)
 0.99
 RRT (n (%))
 83 (24.4)
 29 (31.9)
 54 (21.7)
 0.05
CPIS D1
 6.0 (2.0-11.0)
 5.0 (2.0-9.0)
 6.0 (2.0-11.0)
 0.32
CPIS D3
 7.0 (5.0-13.0)
 7.0 (5.0-11.0)
 7.0 (5.0-13.0)
 0.25
SOFA D1
 8.0 (4.0-17.01)
 9.0 (4.0-16.0)
 8.0 (4.0-17.0)
 0.11
SOFA D3
 8.0 (4.0-18.0)
 8.0 (4.0-15.0)
 8.0 (4.0-18.0)
 0.63
PCT D-1
 1.2 (0.1-172.0)
 1.1 (0.1-55.9)
 1.4 (0.1-172.0)
 0.42
PCT D1
 1.2 (0.1-91.4)
 1.3 (0.1-30.0)
 1.2 (0.1-91.4)
 0.41
PCT D2
 1.5 (0.1-162.0)
 1.4 (0.1-64.3)
 1.6 (0.1-162.0)
 0.28
PCT D3
 1.3 (0.1-345.2)
 1.5 (0.1-56.2)
 1.2 (0.1-345.2)
 0.71
PCT D4
 1.2 (0.1-199.2)
 1.0 (0.1-35.3)
 1.2 (0.1-199.2)
 0.61
Ventilator-free days
 4.0 (0.0-112.0)
 2.0 (0.0-30.0)
 4.0 (0.0-112.0)
 <0.01
Length of ICU stay (days)
 26.0 (4.0-204.0)
 25.0 (4.0-147.0)
 26.0 (5.0-204.0)
 0.80
Duration of MV (days)
 20.0 (2.0-176.0)
 20.0 (2.0-121.0)
 19.0 (2.0-176.0)
 0.42
30-day mortality (n (%)) 100 (28.6) 33 (35.5) 67 (26.2) 0.09

VAP, ventilator-associated pneumonia; ICU, intensive care unit; MV, mechanical ventilation; RRT, renal replacement therapy; CPIS, clinical pulmonary infection score; D, day; SOFA, sequential organ failure assessment; PCT, procalcitonin.